SEC Tracker
Get the app

Abvc Biopharma ABVC

Abvc Biopharma reports $1.15 million net income for Q3 2026

Abvc Biopharma (ABVC) filed a 10-Q with the SEC on Nov 10, 2026, 4:51 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $0 for the three months ended Sep 30, 2026
  2. Net income: $1.15 million for the three months ended Sep 30, 2026
  3. Diluted EPS: $0.04 for the three months ended Sep 30, 2026
  4. Cash and equivalents: $11,294 at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Going-concern warning repeated

“These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going concern.”
In the notes to the financial statements. Read it in the filing 10-Q on EDGAR

Also in the prior 10-Q (filed Aug 12, 2026). Prior report Prior on EDGAR

Quoted from the filing.

Get an email when Abvc Biopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange QoQ
Operating income and margin−$1.24M−$780K−59%
Net income$1.15M−$737K+256%
Operating cash flow−$439K−$244K−80%
Cash$11K$32K−65%

Data on this page was fetched . The filing on SEC.gov is the record.